Monopar Therapeutics (MNPR) Shares Outstanding (2017 - 2026)

Monopar Therapeutics has reported Shares Outstanding (Entity) for 9 years, with the latest figure at $6.7 million in Q4 2025.

• Quarterly Shares Outstanding (Entity) rose 76.56% year-over-year to $6.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.7 million (up 76.56% YoY) and the FY2025 annual result came in at $6.7 million, up 76.56% from the prior year.
• Shares Outstanding (Entity) held at $6.7 million in Q4 2025 per MNPR's latest filing, from $6.7 million in the prior quarter.
• Over five years, Shares Outstanding (Entity) peaked at $6.7 million in Q4 2025 and troughed at $2.5 million in Q1 2021.
• A 5-year average of $3.6 million and a median of $2.8 million in 2023 frame the typical range for Shares Outstanding (Entity).
• The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Entity) grew 0.4% in 2022, then jumped 89.02% in 2025.
• Over 5 years, Shares Outstanding (Entity) stood at $2.5 million in 2021, then grew by 2.77% to $2.6 million in 2022, then increased by 15.12% to $3.0 million in 2023, then grew by 27.15% to $3.8 million in 2024, then surged by 76.56% to $6.7 million in 2025.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $6.7 million, $6.7 million, and $6.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.